Medical Devices News and Research

RSS

Urologix announces fiscal 2009 fourth-quarter and full-year financial results

Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ systems, a durable and effective catheter based in-office alternative to drugs or surgery for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fourth quarter ended June 30, 2009 and for fiscal year 2009.

26 Aug 2009

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

David H. Fater, CEO of Vicor Technologies, Inc., today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management.

26 Aug 2009

FDA recommends electronic report formats to strengthen postmarket safety data collection

The U.S. Food and Drug Administration is proposing to amend postmarket safety reporting regulations for three of its centers to require that manufacturers and other facilities subject to current reporting requirements submit their reports in an electronic format.

26 Aug 2009

Vision-related patient-reported outcomes used for improving medical product labeling in ophthalmology

The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring an October 13 conference to determine how vision-related patient-reported outcomes might be used to improve medical product labeling in ophthalmology.

26 Aug 2009

Boston Scientific Corporation to webcast conference call to discuss results of Landmark MADIT-CRT trial

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing final results from the landmark MADIT-CRT trial on Tuesday, September 1, at 8:00 a.m. ET / 2:00 p.m. Barcelona time.

25 Aug 2009

Comparative effectiveness: Back surgery remains popular despite poor study results

Studies have recently found that vertebroplasty - a type of back surgery in which cement is injected into the spine - isn't effective, but many patients and their doctors insist it works.

25 Aug 2009

Patients suffering from functional and degenerative mitral regurgitation treated using the MitraClip system

Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Karolinska University Hospital in Solna, Stockholm, Sweden.

24 Aug 2009

Prescient Medical's vProtect(TM) Luminal Shield Stent System receives CE Mark approval for treating heart disorders

Medical device pioneer, Prescient Medical, Inc., announced today that it has received European CE Mark (Conformite Europeene) approval to commercialize its vProtect(TM) Luminal Shield Stent System. The device is now approved for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease.

24 Aug 2009

$1.1 million funds will help make critical enhancements to Integrated Medical Systems' MedEx 1000 system

Integrated Medical Systems, Inc., a medical technology systems integrator transforming critical care, announced that it has received $1.1 million in funding from the U.S. Department of Defense for additional enhancements of the company's MedEx 1000(TM) "suitcase" intensive care unit (ICU).

24 Aug 2009

Specialty Silicone Fabricators to expand manufacturing facility

Medical manufacturing is a bright spot in the U.S. economy, as evidenced by Specialty Silicone Fabricators, which is expanding into a new 100,000-square-foot manufacturing facility. The new facility is designed to meet the growing demand for silicone medical device components and support the manufacturing of new medical technologies such as combination products.

21 Aug 2009

Inc. magazine ranks Signature Genomic Laboratories no.1012 on its fastest-growing private companies ranking list

Inc. magazine ranked Signature Genomic Laboratories no. 1012 on its third annual Inc. 5000, an exclusive ranking of the nation's fastest-growing private companies. The company, which performs microarray-based diagnostic genetic testing of chromosome abnormalities in individuals with unexplained mental retardation and/or birth defects, experienced three-year sales growth of 302.9%, more than twice that of the Inc. 5000 industry median and over 12 times the industry benchmark. Signature was also ranked 70th of companies in the healthcare sector.

21 Aug 2009

Synthes to distribute ECM products manufactured by Kensey Nash following a strategic agreement

Synthes, Inc. (SWX: SYST.VX), a leading global medical device company in the orthopaedic trauma, spine, and cranio-maxillofacial markets, and Kensey Nash Corporation (Nasdaq: KNSY), a leading developer and manufacturer of innovative regenerative medicine products, today announced a strategic agreement for products developed from Kensey Nash's unique extracellular matrix (ECM) technology.

21 Aug 2009

Coherex Medical raises $16.5 million from venture capital firms

Coherex Medical, Inc. today announced that it has closed a $16.5 million Series B Preferred Stock financing. After the close of this investment, Coherex has now raised nearly $28.0 million in equity financing from outside funding sources since inception.

21 Aug 2009

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein-a cancer vaccine-that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

21 Aug 2009

Kensey Nash announces financial results for fourth-quarter and full fiscal year 2009

Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its fourth quarter and fiscal year ended June 30, 2009.

20 Aug 2009

Oticon Medical to globally market the FDA approved Ponto bone anchored hearing system

Oticon Medical, a global medical device company within the William Demant Group, announced today that it has obtained 501(k) clearance from the U.S. Food & Drug Administration (FDA) to market the innovative Ponto bone anchored hearing system.

20 Aug 2009

Unaudited financial results of China Medical Technologies to be announced on September 1, 2009

China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that it will report its unaudited financial results for the fourth fiscal quarter ("4Q FY2008") and fiscal year ended March 31, 2009 ("FY2008") and the first fiscal quarter ("1Q FY2009") ended June 30, 2009 before the U.S. market opens on September 1, 2009. The Company's 2009 fiscal year ends on March 31, 2010.

20 Aug 2009

Supplemental Manufacturing and Ingredients forges manufacturing agreement with HealthSport's subsidiary, InnoZen

InnoZen, Inc., a wholly owned subsidiary of HealthSport, Inc. (OTC Bulletin Board: HSPO) announced today that it has entered into a manufacturing agreement with Supplemental Manufacturing and Ingredients, LLC ("SMI"), a cGMP certified manufacturer based in Tempe, Arizona. As part of the Agreement, SMI has committed to purchasing $1,000,000 worth of HealthSport common stock.

20 Aug 2009

Advansource Biomaterials partners with medical device company for the development of specialized solution-based polymer

AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced that the Company has entered into a multi-year development agreement with a leading international medical device company.

20 Aug 2009

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fourth quarter and fiscal year ended June 30, 2009.

19 Aug 2009

Medical Devices News and Research

Urologix announces fiscal 2009 fourth-quarter and full-year financial results

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

FDA recommends electronic report formats to strengthen postmarket safety data collection

Vision-related patient-reported outcomes used for improving medical product labeling in ophthalmology

Boston Scientific Corporation to webcast conference call to discuss results of Landmark MADIT-CRT trial

Comparative effectiveness: Back surgery remains popular despite poor study results

Patients suffering from functional and degenerative mitral regurgitation treated using the MitraClip system

Prescient Medical's vProtect(TM) Luminal Shield Stent System receives CE Mark approval for treating heart disorders

$1.1 million funds will help make critical enhancements to Integrated Medical Systems' MedEx 1000 system

Specialty Silicone Fabricators to expand manufacturing facility

Inc. magazine ranks Signature Genomic Laboratories no.1012 on its fastest-growing private companies ranking list

Synthes to distribute ECM products manufactured by Kensey Nash following a strategic agreement

Coherex Medical raises $16.5 million from venture capital firms

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

Kensey Nash announces financial results for fourth-quarter and full fiscal year 2009

Oticon Medical to globally market the FDA approved Ponto bone anchored hearing system

Unaudited financial results of China Medical Technologies to be announced on September 1, 2009

Supplemental Manufacturing and Ingredients forges manufacturing agreement with HealthSport's subsidiary, InnoZen

Advansource Biomaterials partners with medical device company for the development of specialized solution-based polymer

Cardiovascular Systems' revenues in fourth-quarter of 2009 increases to $15.7 million

Industry Focus - Medical Device eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News